Multi-Level CTO Course 2019

The recanalization of coronary chronic total occlusion (CTO) has become an important procedure to treat symptomatic patients with ischemia or heart failure.. It is a growing and constantly evolving discipline, allowing us to improve our daily practice in percutaneous coronary interventions (PCI). Learning or reviewing the basics, tips & tricks, and mastering CTO techniques is essential to manage complex coronary patients. More and more interventional cardiologists are eager to learn and develop CTO PCI programs in their CathLabs.

Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety and performance of the DyeVert Contrast Reduction System during standard clinical use in a real-world patient population. The DyeMINISH registry is a retrospective, large-scale, multi-center study, with the first patient included on May 7, 2019. The registry is designed to enroll up to 10,000 participants and is expected to complete in late 2023.

Stereotaxis introduced Stereotaxis Genesis RMN, its next-generation robotic platform that it claims is a significant advancement in robotic magnetic navigation technology.

Philips announced a collaboration with Medtronic to further advance treatment of paroxysmal atrial fibrillation (PAF), a common heart rhythm disorder. Through the agreement, Medtronic will facilitate sales of products on behalf of Philips to provide an integrated image guidance solution for cryoablation procedures. Philips will bring to market the novel KODEX-EPD cardiac imaging and navigation system with cryoablation specific features to enable electrophysiologists to perform cryoablation procedures with reduced need for X-ray imaging.

Contemporary Management of Valvular Disease: Diagnosis, Imaging and Intervention

Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it may be a good idea for those who suffer from both atrial fibrillation and heart disease.

This 360 degree photo shows Dee Dee Wang, M.D., director of structural heart imaging, Henry Ford Hospital, Detroit, Mich., shows how a Sapien transcatheter aortic valve replacement (TAVR) valve placed in the inferior vena cava can be used as an interventional treatment of severe tricuspid regurgitation. The procedure is known as the caval valve implantation (CAVI). 

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions. SCAI 2019 late breaking sessions, SCAI featured research sessions.

May 8, 2019 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions will take place May 19-22, 2019 at the Cosmopolitan of Las Vegas in Las Vegas, Nev. The biggest news will be from the featured clinical research sessions that highlight the latest advances in interventional cardiology. Here is at the list of sessions:

 

Transcatheter aortic valve replacement (TAVR) has been studied as an alternative to surgical aortic valve replacement in high and intermediate-risk surgical patients for more than five years. A new clinical trial, one of two studies on the topic presented at the American Association for Thoracic Surgery’s 99th Annual Meeting, May 4-7 in Toronto, finds the procedure to be equivalent or potentially preferable to surgical aortic valve replacement (SAVR) for low-risk patients.

The U.S. Food and Drug Administration (FDA) issued a safety communication to alert healthcare providers and patients about issues that may cause batteries in certain Medtronic implantable pacemakers or cardiac resynchronization therapy pacemakers (CRT-Ps) to drain more quickly than expected without warning.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now